JP2020503841A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020503841A5 JP2020503841A5 JP2019519313A JP2019519313A JP2020503841A5 JP 2020503841 A5 JP2020503841 A5 JP 2020503841A5 JP 2019519313 A JP2019519313 A JP 2019519313A JP 2019519313 A JP2019519313 A JP 2019519313A JP 2020503841 A5 JP2020503841 A5 JP 2020503841A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- disorder
- disease
- cells
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 24
- 108020003175 receptors Proteins 0.000 claims 19
- 102000005962 receptors Human genes 0.000 claims 19
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 208000035475 disorder Diseases 0.000 claims 13
- 201000010099 disease Diseases 0.000 claims 11
- 230000003834 intracellular effect Effects 0.000 claims 11
- 210000002865 immune cell Anatomy 0.000 claims 6
- 230000019491 signal transduction Effects 0.000 claims 6
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 4
- 230000004913 activation Effects 0.000 claims 4
- 210000005260 human cell Anatomy 0.000 claims 4
- 208000030159 metabolic disease Diseases 0.000 claims 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 4
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 claims 3
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 claims 3
- 101001075287 Homo sapiens Growth hormone receptor Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 101150056950 Ntrk2 gene Proteins 0.000 claims 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 208000026278 immune system disease Diseases 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 210000004443 dendritic cell Anatomy 0.000 claims 2
- 208000016097 disease of metabolism Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 206010016165 failure to thrive Diseases 0.000 claims 2
- 208000037824 growth disorder Diseases 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 210000001616 monocyte Anatomy 0.000 claims 2
- 210000000066 myeloid cell Anatomy 0.000 claims 2
- 210000000440 neutrophil Anatomy 0.000 claims 2
- 230000026731 phosphorylation Effects 0.000 claims 2
- 238000006366 phosphorylation reaction Methods 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 206010000599 Acromegaly Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 206010056438 Growth hormone deficiency Diseases 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 229940124060 PD-1 antagonist Drugs 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 208000026928 Turner syndrome Diseases 0.000 claims 1
- 102000007624 ZAP-70 Protein-Tyrosine Kinase Human genes 0.000 claims 1
- 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000002222 downregulating effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims 1
- 208000007345 glycogen storage disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 210000003470 mitochondria Anatomy 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000016515 regulation of signal transduction Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 108091005703 transmembrane proteins Proteins 0.000 claims 1
- 102000035160 transmembrane proteins Human genes 0.000 claims 1
- 230000003827 upregulation Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662406005P | 2016-10-10 | 2016-10-10 | |
| US62/406,005 | 2016-10-10 | ||
| PCT/IL2017/051133 WO2018069927A1 (en) | 2016-10-10 | 2017-10-10 | Non-cytotoxic modified cells and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020503841A JP2020503841A (ja) | 2020-02-06 |
| JP2020503841A5 true JP2020503841A5 (enExample) | 2020-11-12 |
| JP7213799B2 JP7213799B2 (ja) | 2023-01-27 |
Family
ID=61906189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019519313A Active JP7213799B2 (ja) | 2016-10-10 | 2017-10-10 | 非細胞傷害性改変細胞およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12098202B2 (enExample) |
| EP (1) | EP3522936A4 (enExample) |
| JP (1) | JP7213799B2 (enExample) |
| CN (1) | CN110022907A (enExample) |
| AU (1) | AU2017342176A1 (enExample) |
| CA (1) | CA3039774A1 (enExample) |
| IL (1) | IL265962B2 (enExample) |
| WO (1) | WO2018069927A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3093628A1 (en) * | 2018-02-15 | 2019-08-22 | The National Institute for Biotechnology in the Negev Ltd. | Tumor environment-specific expression of chimeric antigen receptors |
| WO2019182910A1 (en) * | 2018-03-19 | 2019-09-26 | Elwha Llc | Compositions and methods for modified b cells expressing reassigned biological agents |
| US20210380700A1 (en) * | 2018-07-06 | 2021-12-09 | Abmax Biopharmaceuticals | De-adcc/cdc functions of antibodies and their applications |
| EA202191929A1 (ru) * | 2019-01-11 | 2021-09-23 | Дзе Уистар Инститьют Оф Энэтоми Энд Байолоджи | Днк-кодируемые моноклональные антитела, нацеленные на pd-1, для лечения и профилактики злокачественного заболевания |
| US20240424167A1 (en) * | 2021-04-27 | 2024-12-26 | Beijing Biosis Healing Biological Technology Co., Ltd. | Chimeric peptide-modified sis membrane, preparation method therefor and application thereof |
| CN117736329B (zh) * | 2023-12-25 | 2024-11-12 | 华润生物医药有限公司 | 抗pd-1抗体及其用途 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7153684B1 (en) | 1992-10-08 | 2006-12-26 | Vanderbilt University | Pluripotential embryonic stem cells and methods of making same |
| US5753225A (en) | 1993-12-03 | 1998-05-19 | The Regents Of The University Of California | Antibodies that mimic actions of neurotrophins |
| US6719972B1 (en) | 1994-06-03 | 2004-04-13 | Repligen Corporation | Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies |
| US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
| EP1025204A4 (en) | 1997-10-23 | 2001-02-28 | Geron Corp | Methods and materials for the growth of primate-derived primordial stem cells |
| US7410798B2 (en) | 2001-01-10 | 2008-08-12 | Geron Corporation | Culture system for rapid expansion of human embryonic stem cells |
| US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| JP2003520828A (ja) | 2000-01-27 | 2003-07-08 | ジェネティクス インスティテュート，エルエルシー | Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用 |
| WO2002059280A2 (en) | 2000-12-08 | 2002-08-01 | Alexion Pharmaceuticals, Inc. | Chronic lymphocytic leukemia cell line and its use for producing an antibody |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| NZ536420A (en) | 2002-04-12 | 2008-04-30 | Medarex Inc | Methods of treatment using CTLA-4 antibodies |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US20060275288A1 (en) * | 2005-01-20 | 2006-12-07 | Grihalde Nelson D | GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof |
| WO2006091209A2 (en) * | 2005-02-23 | 2006-08-31 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents for modulating biological activity |
| CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| KR20080032070A (ko) | 2005-06-06 | 2008-04-14 | 와이어쓰 | 항-ＴｒｋＢ 모노클로날 항체 및 이의 용도 |
| KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
| US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
| US20090227032A1 (en) | 2005-12-13 | 2009-09-10 | Kyoto University | Nuclear reprogramming factor and induced pluripotent stem cells |
| KR101420740B1 (ko) | 2005-12-13 | 2014-07-17 | 교또 다이가꾸 | 핵초기화 인자 |
| US8841255B2 (en) | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
| WO2007142241A1 (ja) | 2006-06-05 | 2007-12-13 | Hiroshima University | 抗ｃｄ３８抗体を細胞表面に有する免疫担当細胞 |
| EP2066337A2 (en) | 2006-08-04 | 2009-06-10 | Amylin Pharmaceuticals, Inc. | Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen |
| US20100135974A1 (en) * | 2007-01-31 | 2010-06-03 | Yeda Research And Development Co. Ltd. | Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease |
| US10155038B2 (en) * | 2007-02-02 | 2018-12-18 | Yale University | Cells prepared by transient transfection and methods of use thereof |
| JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
| US9683232B2 (en) | 2007-12-10 | 2017-06-20 | Kyoto University | Efficient method for nuclear reprogramming |
| CN102015769B (zh) * | 2008-01-17 | 2014-12-10 | Irm责任有限公司 | 改进的抗-trkb抗体 |
| EP2342228B1 (en) | 2008-09-12 | 2017-09-06 | Oxford University Innovation Limited | Pd-1 specific antibodies and uses thereof |
| KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제 |
| US20100261776A1 (en) * | 2008-11-07 | 2010-10-14 | The Research Foundation Of State University Of New York | Bruton's tyrosine kinase as anti-cancer drug target |
| US20120148586A1 (en) * | 2009-08-27 | 2012-06-14 | Joyce Ching Tsu Chou | Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders |
| US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| AR083705A1 (es) * | 2010-11-04 | 2013-03-13 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| US8771696B2 (en) | 2010-11-23 | 2014-07-08 | Regeneron Pharmaceuticals, Inc. | Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor |
| GB2491106A (en) | 2011-05-18 | 2012-11-28 | Univ Basel | Antibodies against tropomyosin-related kinase B receptors |
| JP6673838B2 (ja) * | 2014-02-14 | 2020-04-01 | セレクティスＣｅｌｌｅｃｔｉｓ | 免疫細胞と病的細胞の両方に存在する抗原を標的とするように操作された、免疫療法のための細胞 |
| WO2015142675A2 (en) * | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| WO2016014565A2 (en) * | 2014-07-21 | 2016-01-28 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
| IL303247A (en) * | 2014-12-29 | 2023-07-01 | Novartis Ag | Methods for preparing cells expressing a chimeric receptor antigen |
| US20170151281A1 (en) * | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| CN110699371A (zh) * | 2016-03-18 | 2020-01-17 | 江苏普瑞康生物医药科技有限公司 | 一种基于FcγRⅢa的嵌合基因及其用途 |
| MA45498A (fr) * | 2016-06-16 | 2019-04-24 | Memorial Sloan Kettering Cancer Center | Cellules treg génétiquement modifiées |
-
2017
- 2017-10-10 IL IL265962A patent/IL265962B2/en unknown
- 2017-10-10 WO PCT/IL2017/051133 patent/WO2018069927A1/en not_active Ceased
- 2017-10-10 CA CA3039774A patent/CA3039774A1/en active Pending
- 2017-10-10 EP EP17860345.2A patent/EP3522936A4/en active Pending
- 2017-10-10 AU AU2017342176A patent/AU2017342176A1/en not_active Abandoned
- 2017-10-10 CN CN201780074816.0A patent/CN110022907A/zh active Pending
- 2017-10-10 US US16/340,196 patent/US12098202B2/en active Active
- 2017-10-10 JP JP2019519313A patent/JP7213799B2/ja active Active
-
2024
- 2024-08-21 US US18/810,629 patent/US20250043000A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020503841A5 (enExample) | ||
| JP7195400B2 (ja) | 細胞内抗原に対して指向された単一ドメイン抗体 | |
| Wu et al. | Mechano-regulation of peptide-MHC class I conformations determines TCR antigen recognition | |
| US20220040298A1 (en) | Use of vista agonists and antagonists to suppress or enhance humoral immunity | |
| Maxwell et al. | IL-18 bridges innate and adaptive immunity through IFN-γ and the CD134 pathway | |
| US20220242974A1 (en) | Anti-pd-l1 nanobody and fc fusion protein and application thereof | |
| Tan et al. | Chitosan nanoparticle-based delivery of fused NKG2D–IL-21 gene suppresses colon cancer growth in mice | |
| Wang et al. | New discovery rarely runs smooth: an update on progranulin/TNFR interactions | |
| FI3303396T3 (fi) | Vasta-aineita ox40:ää vastaan ja niiden käyttöjä | |
| Mizui et al. | Immune semaphorins: novel features of neural guidance molecules | |
| EP3687569A1 (en) | Methods of making bispecific anti-cd307e and anti-bcma chimeric antigen receptors and uses of the same | |
| FI3443010T3 (fi) | Uusia anti-sirp -vasta-aineita ja niiden terapeuttisia sovelluksia | |
| Camara et al. | Lymphocyte differentiation and effector functions | |
| CN110092832A (zh) | 抗ox40抗体及其用途 | |
| Zhang et al. | Engineering nano‐clustered multivalent agonists to cross‐link TNF receptors for cancer therapy | |
| Mahesh et al. | Expression of GITR ligand abrogates immunosuppressive function of ocular tissue and differentially modulates inflammatory cytokines and chemokines | |
| Wu et al. | IL-21 signaling promotes IgM+ B cell proliferation and antibody production via JAK/STAT3 and AKT pathways in early vertebrates | |
| Fellermeier-Kopf et al. | Duokines: a novel class of dual-acting co-stimulatory molecules acting in cis or trans | |
| Senthilkumar et al. | CD137L-and RANKL-mediated reverse signals inhibit osteoclastogenesis and T lymphocyte proliferation | |
| Paul et al. | Characterisation of monoclonal antibodies to the TNF and TNF receptor families | |
| Volkov et al. | The impact of the intracellular domains of chimeric antigenic receptors on the properties of CAR T-cells | |
| Sun et al. | Research Note: Development and characterization of monoclonal antibodies specific for chicken interleukin-7 receptor α (CD127) | |
| KR20170031126A (ko) | 수용성 수용체 라이브러리 및 이를 이용한 사이토카인 발현 조절 유전자의 스크리닝 방법 | |
| Daien et al. | AB0024 Regulatory B Cell Functions Are Altered in Patients with Rheumatoid Arthritis and the Impairment of B Cell IL-10 Secretion is not Corrected by Efficient Therapies | |
| Sakaguchi et al. | Costimulation via Glucocorticoid-Induced |